4.5 Review

Post-translational regulation of the β-secretase BACE1

Journal

BRAIN RESEARCH BULLETIN
Volume 126, Issue -, Pages 170-177

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.brainresbull.2016.04.009

Keywords

Alzheimer's disease; Amyloid beta-protein; BACE1; beta-Secretase; Oligomer; Trafficking

Categories

Funding

  1. JSPS, Japan [22590951]
  2. Intramural Research Grant for Neurological and Psychiatric Disorders of the National Center of Neurology and Psychiatry [27-9]
  3. Grants-in-Aid for Scientific Research [16K09688, 25461300, 22590951] Funding Source: KAKEN

Ask authors/readers for more resources

beta-Secretase, widely known as beta-site APP cleaving enzyme 1 (BACE1), is a membrane-associated protease that cleaves amyloid precursor protein (APP) to generate amyloid beta-protein (A beta). As this cleavage is a pathologically relevant event in Alzheimer's disease, BACE1 is considered a viable therapeutic target. BACE1 can be regulated at the transcriptional, post-transcriptional, translational, and post-translational levels. Elucidation of the regulatory pathways of BACE1 is critical, not only for understanding the pathological mechanisms of AD but also developing effective therapeutic strategies to inhibit activity of the protease. This mini-review focuses on the post-translational regulation of BACE1, as modulation at this level is closely associated with both physiological and pathological conditions. Current knowledge on the mechanisms underlying such BACE1 regulation and their implications for therapy are discussed. (C) 2016 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available